CVS Pharmacy suspends sale of Zantac and CVS brand ranitidine products
Category: #health  By Mateen Dalal  Date: 2019-09-30
  • share
  • Twitter
  • Facebook
  • LinkedIn

CVS Pharmacy suspends sale of Zantac and CVS brand ranitidine products

Lately, Carcinogens have found their way into the generic drug supply of the United States. In 2018, FDA found NDMA, a probable carcinogen for humans, in the widely-used valsartan tablets due to the impurities it had in it. 

A similar case developed recently when CVS Pharmacy, a subsidiary of American health and retail company CVS Health, reportedly announced that it has suspended sales of CVS Health brand and Zantac brand ranitidine products until any further notice over a possible link to cancer.

The pharmaceutical firm took this action out of abundance of caution because of the recent Product Alert issued by the Food and Drug Administration (FDA) about ranitidine products containing low levels of NDMA (nitrosodimethylamine), which is a known animal carcinogen and a probable carcinogen in humans.

Reports cite, Zantac’s official recall has not been issued yet. The FDA has not yet recommended patients to stop the consumption of ranitidine presently.

The FDA is currently working to examine if the low levels of NDMA present in ranitidine products are a risk to patient life. The NDMA levels found by FDA in ranitidine from primary tests hardly exceeds the amount of NDMA present in common foods. However, the company claims, people wishing to return their products can return them for a refund.

The FDA stated that people consuming these medicines shouldn't panic, but it also suggested to switch on any other over-the-counter drug alternative to ranitidine while it would test more samples.

Ranitidine is a H2 Blocker that is consumed to get relief from heartburn. The company would continue selling of other H2 Blockers, which would include Tagamet, Pepcid as well as its respective generic equivalents, cimetidine and famotidine.

Another pharmaceutical firm Novartis had already announced that it would no longer supply Zantac’s generic versions because of the discovery.

Sandoz, a subsidiary of Novartis that prepares generic version of Zantac stated that it has not received any reports regarding adverse events pertaining to the use of the drug as a part of the aforementioned recall. It also stated that patients should approach their respective physician and/or pharmacy for any alternative treatment option.

Sanofi, the company which makes Zantac stated that the FDA reported that N-nitrosodimethylamine (NDMA) levels in ranitidine in its initial tests hardly exceed the amounts present in common foods. However, Sanofi is working closely with FDA and is also conducting its own intensive investigations to make sure that it continues to fulfil the greatest standards of quality and safety.

Source credit: https://www.cbsnews.com/news/zantac-carcinogen-cvs-pharmacy-pulls-zantac-generic-brand-over-possible-link-to-cancer-2019-09-29/

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Google’s business intelligence platform Looker collabs with Tableau
Google’s business intelligence platform Looker collabs with Tableau
By Mateen Dalal

Google Cloud Platform has recently revealed that its business intelligence platform, Looker has been integrated with Tableau, empowering users of both the platforms to benefit from the different features offered by each. For starters, Google Cloud a...

HR tech firm Personio ropes in $270 million in latest financing round
HR tech firm Personio ropes in $270 million in latest financing round
By Mateen Dalal

Personio, a HR software provider targeting small and medium sized businesses, has attained a $270 million investment in the wake of high demand for its services. With the latest Series E round of funding, Personio's valuation roses to $6.3 billi...

New Zealand prepares to deal with potential surge in COVID-19 cases
New Zealand prepares to deal with potential surge in COVID-19 cases
By Mateen Dalal

New Zealand is preparing for an increase in Covid-19 cases after registering 94 new infections over the weekend, with pandemic modelers predicting that if the government continues on its present path, new cases would rapidly exceed 100 per day. Epid...